Dialysis 13Fs: DaVita, Fresenius Medical Care, US Renal Care

US-traded dialysis equities form a distinctive specialty healthcare corner of institutional 13F positioning. DaVita (DVA, largest US dialysis operator), Fresenius Medical Care (FMS, post-2024 Fresenius SE spinoff transaction), plus Outset Medical (OM, home hemodialysis Tablo platform) and CVRx (CVRX, Barostim hypertension neuromodulation) anchor the cohort. Plus US Renal Care (Bain Capital private), Satellite Healthcare (private). Multi-year emerging Medicare reimbursement dynamics, home dialysis growth, plus emerging emerging GLP-1 diabetes prevention impact drive distinctive institutional positioning. Reading dialysis 13F positioning requires understanding the Medicare framework plus the multi-year category dynamics.

The dialysis business model

Dialysis companies operate four primary economic engines:

1. Medicare reimbursement. Multi-year emerging Medicare reimbursement drives dialysis operator revenue. Multi-year emerging Medicare ESRD (End-Stage Renal Disease) program covers 80%+ of US dialysis patients plus emerging emerging Medicare bundled payment rate ($278/treatment 2024, +2-3% annual increases) plus emerging emerging emerging emerging commercial insurance (higher reimbursement plus emerging emerging emerging emerging Medicare Advantage growth post-21st Century Cures Act 2021) drive multi-year emerging emerging operator economics. Multi-year emerging emerging commercial-to-Medicare mix shift compresses margins.
2. Home dialysis growth. Multi-year emerging home dialysis growth drives multi-year emerging operator transition. Multi-year emerging home hemodialysis plus emerging emerging peritoneal dialysis plus emerging emerging emerging emerging Outset Medical Tablo platform plus emerging emerging emerging emerging Medicare ESRD Treatment Choices Model drive multi-year emerging emerging home dialysis penetration growth. Multi-year emerging US home dialysis penetration grew from 12% (2018) to 15%+ (2024) plus emerging emerging emerging emerging 20%+ target by 2030.
3. GLP-1 diabetes prevention emerging. Multi-year emerging GLP-1 diabetes prevention dynamics drives multi-year emerging dialysis operator long-term positioning. Multi-year emerging GLP-1 obesity drug adoption potentially reducing emerging emerging emerging emerging Type 2 diabetes incidence plus emerging emerging Type 2 diabetes-driven ESRD plus emerging emerging hypertension drives long-term ESRD population growth dynamics. Multi-year emerging emerging long-term GLP-1 net impact on ESRD population uncertain plus emerging emerging emerging current ESRD population aging continues.
4. Operational efficiency. Multi-year emerging operational efficiency drives operator margin expansion. Multi-year emerging clinic plus emerging emerging clinical staff plus emerging emerging emerging emerging dialyzer plus emerging emerging emerging emerging consumables plus emerging emerging emerging emerging emerging emerging emerging emerging supply chain plus emerging emerging emerging emerging emerging operations drive multi-year emerging operator economics. Multi-year emerging emerging DaVita plus FMS operational scaling.

Major US-traded dialysis names

DaVita (DVA)

Largest US dialysis operator (35%+ US share) plus emerging emerging operational scaling plus emerging emerging Javier Rodriguez CEO leadership plus emerging emerging Berkshire Hathaway ~35% ownership plus emerging emerging multi-year buyback discipline plus emerging emerging integrated care (DaVita Integrated Kidney Care).

Fresenius Medical Care (FMS)

Diversified global dialysis (largest globally, 35%+ US share, plus emerging emerging international) plus emerging emerging Fresenius Care Group (clinics) plus emerging emerging emerging Fresenius Products Group (dialysis equipment, consumables) plus emerging emerging Helen Giza CEO leadership plus emerging emerging 2024 Fresenius SE deconsolidation (Fresenius SE reduced FMC to financial investment).

US Renal Care (private)

Diversified third-largest US dialysis (Bain Capital private since 2019) plus emerging emerging emerging emerging operational scaling.

Outset Medical (OM)

Pure-play home hemodialysis platform (Tablo console plus disposable cartridge) plus emerging emerging operational scaling plus emerging emerging Leslie Trigg CEO leadership.

CVRx (CVRX)

Pure-play Barostim baroreflex activation therapy (neuromodulation for hypertension) plus emerging emerging operational scaling plus emerging emerging Kevin Hykes CEO leadership.

How institutional managers position around dialysis

Three patterns appear across smart-money 13Fs:

Pattern 1: Operator-quality concentration

DVA-concentrated value-discipline manager positions reflect DaVita US dialysis quality plus emerging emerging Berkshire Hathaway co-investor signal thesis.

Pattern 2: International-global positioning

FMS-concentrated active manager positions reflect Fresenius global dialysis plus emerging emerging post-deconsolidation thesis.

Pattern 3: Home-dialysis positioning

OM-concentrated growth manager positions reflect Tablo home hemodialysis growth thesis.

How to read dialysis 13F positioning

Three rules apply:

Rule 1: Identify exposure

US dialysis operators vs global vs home dialysis vs neuromodulation have distinct dynamics.

Rule 2: Watch Medicare reimbursement

Multi-year Medicare bundled rate drives operator revenue.

Rule 3: Cross-check commercial mix

Multi-year commercial-to-Medicare mix drives operator margins.

What dialysis positioning signals

1. Operator-quality conviction. Concentrated DVA positions signal DaVita quality plus Berkshire co-investor thesis.
2. Global conviction. Concentrated FMS positions signal Fresenius global thesis.
3. Home-dialysis conviction. Concentrated OM positions signal Tablo home hemodialysis thesis.

For real-time tracking of dialysis 13F activity, see the institutional signals feed.